LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 320

Search options

  1. Article ; Online: Evidence in support of the bone marrow as the primary lesion in axial spondyloarthritis.

    Maksymowych, Walter P

    Current opinion in rheumatology

    2023  Volume 35, Issue 4, Page(s) 213–218

    Abstract: Purpose of review: Over the past several decades, the concept that the primary lesion accounting for the development of axSpA is an enthesopathy has been widely accepted. However, the hallmark abnormality of axSpA occurs in the sacroiliac joint at the ... ...

    Abstract Purpose of review: Over the past several decades, the concept that the primary lesion accounting for the development of axSpA is an enthesopathy has been widely accepted. However, the hallmark abnormality of axSpA occurs in the sacroiliac joint at the interface of cartilage and bone at a location remote from any anatomical enthesis. Both imaging and histopathological data from the sacroiliac joint point to immunopathogenetic events in the bone marrow as being of primary importance. Here, we discuss new developments in our understanding of immune events in the bone marrow relevant to axSpA that reinforce the need for a change in our conceptual paradigm for the pathogenesis of axSpA.
    Recent findings: Human spinal enthesis samples contain myeloperoxidase-expressing cells, a marker of neutrophils, and mucosal-associated invariant T cells in the perientheseal bone marrow, which may be activated by stromal cells and circulating microbial products to express IL-17A and IL-17F and tumor necrosis factor (TNF). Evaluation of transcriptomes of monocytes from patients with axSpA demonstrates a lipopolysaccharide/TNF signature characterized by the expression of genes associated with granulocytopoietic bone marrow cells. This neutrophil-like phenotype is more evident in established and more severe axSpA and may be activated by microbial products from the gut. A similar expansion of granulocyte-monocyte progenitor-driven hematopoiesis occurs in the SKG mouse driven by granulocyte-macrophage colony-stimulating factor. Mesenchymal stem cells (MSCs) from ankylosing spondylitis patients are more likely to exhibit osteogenic differentiation than MSCs from healthy donors, which may be mediated by the formation of specific clusters of transcriptional factors, super enhancers, regulated by axSpA-associated single nucleotide polymorphisms located mostly in noncoding regions. TNF-α may enhance directional migration of AS-MSC compared with MSC from healthy controls from the bone marrow to entheseal soft tissue, which is mediated by increased expression of engulfment and cell motility protein 1 (ELMO1). TNF and IL-17A display differential effects on adipogenesis and osteogenesis of MSC in perientheseal bone marrow and soft tissue.
    Summary: Bone marrow has the capacity to undergo rapid adaptation in terms of cell composition, differentiation, and immune function, resulting in inflammation and osteogenesis in axSpA.
    MeSH term(s) Humans ; Animals ; Mice ; Interleukin-17/metabolism ; Bone Marrow ; Osteogenesis ; Spondylitis, Ankylosing/metabolism ; Cell Differentiation ; Tumor Necrosis Factor-alpha ; Spondylarthritis ; Adaptor Proteins, Signal Transducing/metabolism
    Chemical Substances Interleukin-17 ; Tumor Necrosis Factor-alpha ; ELMO1 protein, mouse ; Adaptor Proteins, Signal Transducing
    Language English
    Publishing date 2023-04-27
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000945
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The paradigm of non-radiographic sacroiliitis-why the ongoing doubts?

    Maksymowych, Walter P

    Clinical rheumatology

    2021  Volume 40, Issue 2, Page(s) 443–446

    MeSH term(s) Humans ; Longitudinal Studies ; Magnetic Resonance Imaging ; Sacroiliac Joint/diagnostic imaging ; Sacroiliitis/diagnostic imaging ; Spondylarthritis
    Language English
    Publishing date 2021-01-06
    Publishing country Germany
    Document type Editorial
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-020-05527-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Advances in the Evaluation of Peripheral Enthesitis by Magnetic Resonance Imaging in Patients With Psoriatic Arthritis.

    Østergaard, Mikkel / Maksymowych, Walter P

    The Journal of rheumatology

    2023  Volume 50, Issue Suppl 2, Page(s) 18–22

    Abstract: Enthesitis is a key disease manifestation in patients with psoriatic arthritis (PsA) that considerably contributes to pain, lower physical function, and reduced quality of life. Clinical assessment of enthesitis lacks sensitivity and specificity, and ... ...

    Abstract Enthesitis is a key disease manifestation in patients with psoriatic arthritis (PsA) that considerably contributes to pain, lower physical function, and reduced quality of life. Clinical assessment of enthesitis lacks sensitivity and specificity, and therefore better methods are urgently needed. Magnetic resonance imaging (MRI) allows detailed assessment of the components of enthesitis, and consensus-based validated MRI scoring systems exist. These include the Outcome Measures in Rheumatology (OMERACT) Heel Enthesitis MRI Scoring System (HEMRIS) method, which assesses the entheses of the heel region in a detailed manner, and the OMERACT MRI Whole-Body Score for Inflammation in Peripheral Joints and Entheses (MRI-WIPE) method, which provides an overall assessment of the inflammatory burden in the peripheral entheses and joints in the entire body using whole-body MRI. At an MRI workshop at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 meeting in Brooklyn, the MRI appearances of peripheral enthesitis were described, as were the scoring methods. The utility of MRI for improved assessment of enthesitis was demonstrated with examples of patient cases. Clinical trials in PsA that evaluate enthesitis by MRI as a key endpoint should include the presence of MRI enthesitis as an inclusion criterion, and apply validated MRI outcomes to assess the effect of therapeutics on enthesitis are recommended.
    MeSH term(s) Humans ; Arthritis, Psoriatic/diagnostic imaging ; Arthritis, Psoriatic/drug therapy ; Quality of Life ; Psoriasis ; Inflammation ; Enthesopathy/diagnostic imaging ; Magnetic Resonance Imaging/methods
    Language English
    Publishing date 2023-07-07
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    DOI 10.3899/jrheum.2023-0518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book: Atlas of magnetic resonance imaging abnormalities in the spine in spondyloarthritis

    Maksymowych, Walter P.

    definitions, reliability, training, and conceptual framework ; a report from the Canada (SPARCC)-Denmark International Spondyloarthritis Working Group

    (Journal of rheumatology : Supplement ; 84)

    2009  

    Institution Canada Denmark International Spondyloarthritis Working Group
    Author's details guest ed. Walter P. Maksymowych
    Series title Journal of rheumatology : Supplement ; 84
    Journal of rheumatology
    Journal of rheumatology ; Supplement
    Collection Journal of rheumatology
    Journal of rheumatology ; Supplement
    Language English
    Size 57 S. : Ill.
    Publisher Journal of Rheumatology Publ
    Publishing place Toronto, ON
    Publishing country Canada
    Document type Book
    HBZ-ID HT016199583
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  5. Article: What Constitutes a Positive MRI for Clinical Trial Recruitment of Psoriatic Arthritis Patients With Axial Involvement?

    Maksymowych, Walter P / Østergaard, Mikkel

    The Journal of rheumatology

    2022  Volume 49, Issue 6 Suppl 1, Page(s) 72–74

    Abstract: There has been a resurgence of interest in defining the axial inflammation component of psoriatic arthritis (PsA) since recent randomized controlled trials (RCTs) raised the possibility that this entity may respond differentially to therapeutics compared ...

    Abstract There has been a resurgence of interest in defining the axial inflammation component of psoriatic arthritis (PsA) since recent randomized controlled trials (RCTs) raised the possibility that this entity may respond differentially to therapeutics compared to patients with axial spondyloarthritis. A workshop was conducted during the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis annual meeting to review the literature on diagnosing PsA and to determine which criteria might be most appropriate. There was quite strong agreement that magnetic resonance imaging (MRI) had an important role to play in helping to define axial inflammation in PsA and that a data-driven methodology for generating optimal MRI quantitative cut-offs for lesions in the sacroiliac joints and/or spine that reflect imaging typical of axial inflammation in PsA would be most desirable.
    MeSH term(s) Arthritis, Psoriatic/diagnostic imaging ; Arthritis, Psoriatic/drug therapy ; Humans ; Inflammation/pathology ; Magnetic Resonance Imaging ; Psoriasis/pathology ; Sacroiliac Joint/diagnostic imaging ; Sacroiliac Joint/pathology
    Language English
    Publishing date 2022-03-15
    Publishing country Canada
    Document type Journal Article ; Review
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    DOI 10.3899/jrheum.211340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Thirteenth International Congress on Spondyloarthritides.

    Ciccia, Francesco / Maksymowych, Walter P

    Clinical and experimental rheumatology

    2022  Volume 40, Issue 9, Page(s) 1817–1910

    Language English
    Publishing date 2022-08-30
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/4spc2y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy.

    Maksymowych, Walter P

    Frontiers in immunology

    2019  Volume 10, Page(s) 305

    Abstract: There exists a major unmet need for biomarkers that can identify axial spondyloarthritis (axSpA) early after disease onset because of the availability of highly effective therapies. Several recent reports have examined the autoantibody response in ... ...

    Abstract There exists a major unmet need for biomarkers that can identify axial spondyloarthritis (axSpA) early after disease onset because of the availability of highly effective therapies. Several recent reports have examined the autoantibody response in patients with axSpA through the use of protein microarrays and protein-protein interactions although diagnostic performance of biomarkers identified to date has been inadequate. An example of such a biomarker is protein phosphatase magnesium-dependent 1A. Antibodies to the human leukocyte antigen class II-associated invariant chain peptide (anti-CD74) are candidate diagnostic biomarkers but sensitivity declines with increasing duration of disease. Metabolomic studies have employed nuclear magnetic resonance (NMR) spectrometry to identify disease-specific metabolites related to fat metabolism and intestinal microbial metabolism. A second major unmet need exists for biomarkers of disease activity that have superiority over standard C-reactive protein assessment and reflect MRI inflammation in the axial spine. Several biomarkers reflecting inflammation (calprotectin), angiogenesis (vasoactive endothelial growth factor), and connective tissue turnover (C2M, C3M, and citrullinated metalloproteinase degraded fragment of vimentin) have recently been shown to reflect disease activity when compared with clinical outcomes but comparisons with MRI inflammation are very limited. With increasing availability of highly effective but costly therapies, a third unmet need is biomarkers that can predict response to therapies with different mechanisms of action and are superior to C-reactive protein. Calprotectin is currently the only candidate. Although there are as yet no proven therapies for preventing progression of disease there is an unmet need for biomarkers of prognosis that are more responsive than radiography. Aside from CRP no consistent candidates have emerged. Future studies will need to be prospective, include consecutive patients presenting with undiagnosed back pain, and use more reliable and objective endpoints such as MRI inflammation. Moreover, it has become evident that targeted biomarker studies have not been successful in identifying clinically useful biomarkers and technologies that can simultaneously assess "multiomic" markers will need to be analyzed for future advances. These include more sophisticated metabolomic profiling and universal metabolome-standard (UMS) methodology, next generation RNA sequencing, and affinity-based quantitative proteomics based on the use of nucleic acid binders such as the aptamer-based SOMAscan assay.
    MeSH term(s) Biomarkers ; Humans ; Prognosis ; Spondylitis, Ankylosing/diagnosis ; Spondylitis, Ankylosing/genetics ; Spondylitis, Ankylosing/immunology ; Spondylitis, Ankylosing/therapy ; Transcriptome
    Chemical Substances Biomarkers
    Language English
    Publishing date 2019-03-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2019.00305
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The role of imaging in the diagnosis and management of axial spondyloarthritis.

    Maksymowych, Walter P

    Nature reviews. Rheumatology

    2019  Volume 15, Issue 11, Page(s) 657–672

    Abstract: MRI of the sacroiliac joints is increasingly acknowledged as being indispensable in the early diagnosis of axial spondyloarthritis (axSpA) and as having a prominent role in the prognosis and classification of axSpA. Technological advances include ... ...

    Abstract MRI of the sacroiliac joints is increasingly acknowledged as being indispensable in the early diagnosis of axial spondyloarthritis (axSpA) and as having a prominent role in the prognosis and classification of axSpA. Technological advances include improvements in the resolution of structural lesions and in methodologies for the quantification of lesions. Limited access and expertise in interpretation of MRI have led to a resurgence of interest in CT, especially the development of low radiation protocols for assessing the sacroiliac joints. Trials of TNF inhibitors in patients with non-radiographic axSpA have led to greater understanding of the role of MRI in selecting which patients might respond well to this therapy. The role of MRI features as target end points in treat-to-target strategies remains unclear because the effect of such targeting on structural damage parameters has only recently been explored. The relative importance of active and structural lesions for prognostic risk assessment and selection of appropriate treatment is also an area of current research. Given the increased capacity to visualize a broad array of lesions in both the sacroiliac joints and the spine using MRI and CT, these modalities will probably be increasingly employed for assessment of the disease-modifying activity of new therapies.
    MeSH term(s) Early Diagnosis ; Humans ; Magnetic Resonance Imaging/methods ; Prognosis ; Sacroiliac Joint/diagnostic imaging ; Spondylarthritis/diagnosis
    Language English
    Publishing date 2019-10-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-019-0309-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.

    Keeling, Stephanie / Maksymowych, Walter P

    Expert review of clinical immunology

    2021  Volume 17, Issue 7, Page(s) 701–715

    Abstract: Introduction: Psoriatic arthritis (PsA) and spondyloarthritis (SpA) are inflammatory arthritides associated with progressive damage, deformity and morbidity. Janus kinase (JAK) inhibitors block JAKs, cytoplasmic protein tyrosine kinases important in ... ...

    Abstract Introduction: Psoriatic arthritis (PsA) and spondyloarthritis (SpA) are inflammatory arthritides associated with progressive damage, deformity and morbidity. Janus kinase (JAK) inhibitors block JAKs, cytoplasmic protein tyrosine kinases important in signal transduction and immune processes that are currently being studied as synthetic disease modifying anti-rheumatic drugs (tsDMARDs) in psoriatic arthritis and spondyloarthritis.
    Areas covered: This review evaluates published phase 2 and 3 clinical trial data for JAK kinase inhibitors for psoriatic arthritis and spondyloarthritis. A literature search using PubMed was conducted using the following keywords: 'psoriatic arthritis', 'ankylosing spondylitis', 'axial spondyloarthritis', 'non-radiographic axial spondyloarthritis', 'tofacitinib', 'baricitinib', 'filgotinib' and 'upadacitinib'. Mechanism of action, phase 2 and 3 clinical trial data, including efficacy and safety, are discussed.
    Expert opinion: JAK inhibitors are important orally administered agents conferring different degrees of selectivity toward JAK1, JAK2, and JAK3 which may have implications on efficacy and safety in PsA and SpA. Phase 2 and 3 clinical trials in PsA for tofacitinib and upadacitinib and phase 2 for filgotinib confirmed efficacy comparable to biologic DMARDs. In SpA, phase 2 and 2/3 studies confirmed significant efficacy of tofacitinib, filgotinib and upadacitinib compared to placebo. Safety was comparable to clinical trial, long-term extension, and registry data for rheumatoid arthritis.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Psoriatic/drug therapy ; Arthritis, Rheumatoid/drug therapy ; Axial Spondyloarthritis ; Humans ; Janus Kinase Inhibitors/therapeutic use
    Chemical Substances Antirheumatic Agents ; Janus Kinase Inhibitors
    Language English
    Publishing date 2021-05-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2021.1925541
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Magnetic Resonance Imaging of Axial and Peripheral Disease in Psoriatic Arthritis: A Report From the 2020 GRAPPA Annual Meeting.

    Maksymowych, Walter P / Østergaard, Mikkel

    The Journal of rheumatology

    2021  

    Abstract: Psoriatic arthritis (PsA) presents with diverse features of musculoskeletal inflammation that affect both axial and peripheral joints as well as entheses, tenosynovium, and bursae. Magnetic resonance imaging (MRI) is the imaging modality that is uniquely ...

    Abstract Psoriatic arthritis (PsA) presents with diverse features of musculoskeletal inflammation that affect both axial and peripheral joints as well as entheses, tenosynovium, and bursae. Magnetic resonance imaging (MRI) is the imaging modality that is uniquely capable of identifying pathology in all these structures. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Magnetic Resonance Imaging Working Group has increasingly explored diverse MRI methodologies for the purposes of quantifying inflammatory and structural abnormalities in clinical trials and research. The 2020 GRAPPA virtual workshop presented an opportunity to review progress in the field, summarize the status of MRI scoring systems developed for PsA, and review representative patient cases.
    Language English
    Publishing date 2021-02-15
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    DOI 10.3899/jrheum.201676
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top